CURRENT
ISSUE
1722

Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.

THE DISORDER — Atopic dermatitis (also known as...  Continue reading

Coming Soon
Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis
Acoramidis (Attruby) for Transthyretin Amyloid Cardiomyopathy
Guselkumab (Tremfya) for Ulcerative Colitis
Drugs for Allergic Rhinitis and Allergic Conjunctivitis